
Investigating the Impact of the Microbiome on CAR T-Cell Therapy Outcomes
Chimeric antigen receptor (CAR) T-cell therapy is a groundbreaking treatment for hematologic malignancies, particularly B-cell malignancies. However, 60% of patients who receive CAR T-cell therapy experience relapse of their underlying disease within 12 …